Alumis reports strong Phase 3 data for envudeucitinib in psoriasis, plans NDA submission in Q4 2026

Alumis Inc. announced positive Phase 3 clinical trial results for envudeucitinib, showing rapid and lasting improvements in moderate-to-severe plaque psoriasis, including high rates of skin clearance and itch relief. The company remains on track to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2026. Additionally, Alumis reported mixed results for envudeucitinib in systemic lupus erythematosus (SLE), with promising responses in a specific patient subgroup. Financially, Alumis ended Q3 2026 with $431.3 million in cash and marketable securities and expects to fund operations into late 2027.

Alumis Inc. shares trade at USD 6.17 on Pluang, down 6.80% as of Nov 13, 2026 04:11 WIB. The stock's market cap stands at $883.74 million, with a 52-week low of $5.24 and a high of $30.30. Trading volume is 1,282,890, and typical holding time is 16 days, reflecting active investor interest despite recent price declines.